Telomir Pharmaceuticals (TELO) Free Cash Flow (2023 - 2025)
Telomir Pharmaceuticals (TELO) posted Free Cash Flow of -$1.2 million for Q4 2025, down 33.33% sequentially from -$900000.0 in Q3 2025, and down 98.08% YoY from -$62.6 million in Q4 2024.
Telomir Pharmaceuticals (TELO) Free Cash Flow (2023 - 2025) Analysis & Trends
Telomir Pharmaceuticals has reported Free Cash Flow for 3 years, with the latest figure at -$1.2 million in Q4 2025.
- Quarterly Free Cash Flow fell 98.08% year-over-year to -$1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.7 million (up 27.03% YoY) and the FY2025 annual result came in at -$3.7 million, up 27.03% from the prior year.
- Free Cash Flow slipped to -$1.2 million in Q4 2025 per TELO's latest filing, from -$900000.0 in the prior quarter.
- Over five years, Free Cash Flow peaked at -$33577.0 in Q2 2023 and troughed at -$2.0 million in Q3 2023.
- A 3-year average of -$1.1 million and a median of -$951181.0 in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow tumbled 4435.38% in 2024, then soared 54.03% in 2025.
- Over 3 years, Free Cash Flow stood at -$1.1 million in 2023, then surged by 44.28% to -$605808.0 in 2024, then tumbled by 98.08% to -$1.2 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$1.2 million, -$900000.0, and -$700000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Telomir Pharmaceuticals | 69.05 Mn | 69.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.20 Mn |
| Dec 31, 2025 | -1.20 Mn |
| Sep 30, 2025 | -900,000.00 |
| Sep 30, 2025 | -900,000.00 |
| Jun 30, 2025 | -700,000.00 |
| Jun 30, 2025 | -700,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Dec 31, 2024 | -605,808.00 |
| Dec 31, 2024 | -605,808.00 |
| Sep 30, 2024 | -1.00 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Jun 30, 2024 | -1.52 Mn |
| Jun 30, 2024 | -1.52 Mn |
| Mar 31, 2024 | -1.94 Mn |
| Mar 31, 2024 | -1.94 Mn |
| Dec 31, 2023 | -1.09 Mn |
| Dec 31, 2023 | -1.09 Mn |
| Sep 30, 2023 | -2.00 Mn |
| Sep 30, 2023 | -2.00 Mn |